FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
632 letters match. Newest first.
-
DrugsKenil Healthcare Private Limited
FDA warns Kenil Healthcare over adulterated drugs from India due to cleaning, packaging, and quality failures.
High risk -
DrugsZhejiang Huahai Pharmaceutical Co., Ltd.
FDA warns Zhejiang Huahai Pharmaceutical over CGMP violations including dirty equipment, aseptic-area tape, and data integrity issues.
High risk -
DrugsHorizon Tool Inc.
FDA warns Horizon Tool over manufacturing-rule violations for AllShield E2 Sanitizing Hand Soap.
High risk -
DrugsLaboratoire Druide Inc.
FDA warned Laboratoire Druide that its OTC drugs are adulterated because of inadequate glycerin identity testing, system validation and cleaning.
High risk -
DrugsAmish Origins Management, LLC
FDA warned Amish Origins over manufacturing quality failures and unapproved or misbranded OTC pain relief and lip balm products.
High risk -
DrugsCTK OTC Laboratories LLC formerly FMK LABS, Inc.
CTK OTC Laboratories, formerly FMK Labs, failed to investigate out-of-spec results and validate processes for OTC drugs, including sunscreens.
High risk -
DrugsEvi Labs LLC
FDA warns Evi Labs over OTC drug manufacturing failures, including an antiperspirant lot above the aluminum chlorohydrate limit.
High risk -
DrugsZhejiang Easyclean Daily Chemical Co., Ltd
FDA warned Zhejiang Easyclean Daily Chemical that its OTC drugs lacked required testing and manufacturing controls.
High risk -
DrugsRechon Life Science AB
FDA warns Swedish sterile drugmaker Rechon Life Science over aseptic technique, weak investigations, cleaning and facility problems.
High risk -
DrugsYiling Pharmaceutical Ltd.
FDA warns Yiling Pharmaceutical over manufacturing violations causing cross-contamination risks in finished drugs from shared equipment.
High risk -
DrugsHuangshi Hygienic Material Medicine Co., Ltd.
Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.
High risk -
DrugsAACE Pharmaceuticals, Inc.
AACE Pharmaceuticals distributed adulterated Lubricant PM Ointment made by CMO Brassica with CGMP violations and failed supplier qualification.
High risk -
DrugsProduct Society LLC
FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.
High risk -
DrugsWuxi Medical Instrument Factory Co., Ltd.
FDA warns Wuxi Medical Instrument Factory over insanitary conditions and manufacturing failures for sterile drugs.
High risk -
DrugsNWL Netherlands Services B.V.
FDA cites NWL Netherlands drug plant for inadequate microbial investigations, missing component identity testing, and weak lab data controls.
High risk -
DrugsExcelvision Fareva
Excelvision Fareva, a sterile drug manufacturer, was cited for inadequate mold/black-speck complaint investigations and aseptic contamination controls.
High risk -
DrugsNingbo Riway Industrial Co., Ltd.
Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.
High risk -
DrugsOSRX, Inc.
OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.
High risk -
DrugsMentha & Allied Products Private Ltd.
FDA warns Mentha & Allied Products of CGMP failures that leave its APIs adulterated.
High risk -
DrugsShantou S.E.Z. Baojie Industry Co., Ltd.
FDA warns Shantou S.E.Z. Baojie Industry over inadequate CGMP and component testing for OTC drug products, leading to Import Alert 66-40.
High risk -
DrugsTailstorm Health Inc. dba Medivant Health
Tailstorm Health (Medivant Health) sterile compounded drugs had insanitary conditions and current good manufacturing practice failures, prompting a bevacizumab recall.
High risk -
DrugsTaizhou Jingshang Cosmetics Technology Co., Ltd.
FDA warns Taizhou Jingshang Cosmetics Technology over current good manufacturing practice failures in over-the-counter drugs, including missing identity tests for high-risk ingredients.
High risk -
DrugsBioAsia Worldwide Sdn Bhd
FDA warned BioAsia Worldwide over current good manufacturing practice violations for OTC drugs.
High risk -
DrugsCosco International, Inc.
FDA warned Cosco International over nonprescription drug manufacturing failures and unapproved drug products.
High risk -
DrugsDyno Manufacturing, Inc.
Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.
High risk -
DrugsBEO Pharma Inc. dba BEO Pharmaceuticals Inc.
FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.
High risk -
DrugsEmpower Clinic Services, LLC dba Empower Pharma
FDA warns Empower Pharma over sterile drug manufacturing deficiencies, labeling, and unapproved compounded drugs after August 2024 inspection.
High risk -
DrugsPMS4PMS, LLC
FDA warns PMS4PMS of Clarence, NY, over CGMP failures and an unapproved menstrual cramp relief cream.
High risk -
DrugsNubratori, Inc. dba Nubratori Rx
FDA cited Nubratori Rx, a sterile compounding outsourcing facility, for insanitary conditions and manufacturing quality failures that may contaminate its drug products.
High risk -
DrugsYangzhou Sion Commodity Co., Ltd.
FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.
High risk -
DrugsAnnovex Pharma, Inc.
FDA warns outsourcing facility Annovex Pharma in Lorton, VA, over contaminated sterile drug production and missed FDA reports.
High risk -
DrugsAspen Biopharma Labs Private Limited
FDA warns Aspen Biopharma Labs over current good manufacturing practice failures in active ingredient manufacturing after U.S. recall.
High risk -
DrugsHangzhou Glamcos Biotech Co., Ltd.
Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.
High risk -
DrugsAdvanced Pharmaceutical Technology
FDA warns Advanced Pharmaceutical Technology over drug manufacturing quality failures, sterility controls, and unapproved drugs.
High risk -
DrugsNeva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi
FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.
High risk -
DrugsInternational Laboratories Corp
FDA warned International Laboratories Corp, a Thai drug manufacturer, over fabricated lab records and inadequate CGMP controls.
High risk -
DrugsAspen Pharmacare Holdings Limited
FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.
High risk -
DrugsRite-Kem Incorporated
FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.
High risk -
DrugsVegewax Candleworx Ltd.
FDA warns Vegewax Candleworx over CGMP violations in OTC drug manufacturing, including inadequate component testing and OOS investigations.
High risk -
DrugsShree Jaya Laboratories PVT. LTD.
FDA warned Shree Jaya Laboratories after an inspection found CGMP deviations in API and intermediate manufacturing, including dirty equipment and torn batch records.
High risk -
DrugsLinghai ZhanWang Biotechnology Co., Ltd
Linghai ZhanWang Biotechnology's OTC drugs, including antimicrobial wipes, fail manufacturing quality rules; FDA cites missing tests.
High risk -
DrugsRight Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals
FDA warned outsourcing facility Carie Boyd Pharmaceuticals in Irving, TX that sterile drug production had airflow, media fill and contamination control failures.
High risk -
DrugsProRx, LLC
FDA warns ProRx, LLC about insanitary sterile compounded-drug production and manufacturing-quality failures.
High risk -
DrugsGranules India Limited
FDA warned Granules India in Telangana, India, that its finished drugs are adulterated after inspectors found cross-contamination in air ducts, bird droppings and torn records.
High risk -
DrugsChem-Tech, Ltd.
Chem-Tech, Ltd. lacked adequate investigations and clean equipment for its OTC drug.
High risk -
DrugsZenzi Pharmaceutical Industries Pvt. Ltd.
Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.
High risk -
DrugsMarshalls Traditional Healthcare CC
Marshalls Traditional Healthcare, an OTC drug maker in South Africa, lacked finished-product release testing and process validation.
High risk -
DrugsABR Laboratory LLC
FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.
High risk -
DrugsTyche Industries Ltd
FDA warned Tyche Industries over falsified records, dirty equipment, and untested raw materials at its API plant.
High risk -
DrugsJagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals cited for API CGMP and listing failures after Indian inspection, leading to US import alert.
High risk